Astellas Pharma Inc (Astellas) focuses on the discovery, development, production, and marketing of drugs for gene therapy, urology, nephrology, immunology, oncology and others. The company is involved in the Rx (prescription drug) business, with 18 R&D programs currently underway. Additionally, Astellas advances its Rx+ business, which encompasses diagnostic, preventive, therapeutic, and prognostic care. The company operates with R&D and manufacturing bases in Japan, the US, Europe, and Asia. The company operates 11 manufacturing bases globally and has a presence in approximately 70 countries.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Astellas conducts R&D in various areas such as urology, oncology, immunology, nephrology, and neuroscience. The company initiates its R&D with exploratory research to identify disease mechanisms and potential compounds, which are converted into drugs in optimization research. The company focuses on cutting-edge technologies such as cell therapy and gene therapy to provide innovative healthcare treatments addressing the root causes of diseases. The primary focus areas include genetic regulation, immuno-oncology, blindness and regeneration, and targeted protein degradation. Astellas also emphasizes partnering to deliver scientific innovations and address unmet medical needs, with current areas of interest including oncology, rare diseases, immuno-sciences, and emerging areas of drug discovery and development. The company's R&D pipeline includes several products targeting various diseases. Its major pipeline products include an antibody-drug conjugate (ADC) targeting Nectin-4 for muscle-invasive bladder cancer, gilteritinib for acute myeloid leukemia, and zolbetuximab for gastric cancer. Additionally, enfortumab vedotin is in development for bladder cancer, while fezolinetant addresses vasomotor symptoms. Gene therapies like resamirigene bilparvovec for X-linked myotubular myopathy and zocaglusagene nuzaparvovec for Pompe disease are also notable. Other innovative therapies include ASP1570 and ASP2138, targeting various cancers. In FY2025, the company’s R&D expenditure stood at JPY327,651 million which as a percentage of revenue stood at 17.1% and grew 11.4% YoY.